Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Invitae And ArcherDX Will Merge To Create Comprehensive Cancer Testing Offering

Executive Summary

The $1.4bn deal will combine Invitae’s centralized laboratory capabilities with ArcherDX’s precision oncology technologies.

You may also be interested in...



BD Expects Alaris Infusion Pump To Return To US Market Next Year

The company stopped shipping Alaris in early 2020 after the FDA requested a new 510(k) for modifications and the device has been the subject of several recalls since then.

NeoGenomics Bolsters Liquid Diagnostics Portfolio By Acquiring Inivata

Inivata will remain a separate liquid biopsy division alongside NeoGenomics’ growing clinical, pharma and informatics divisions.

Labcorp Buys Myriad Genetics’ Vectra Autoimmune Test Business

Labcorp has agreed to pay $150m in cash for Myriad Genetics’ autoimmune business, one of three major units Myriad is unloading as it tries to narrow its focus to oncology, women's health and mental health diagnostics.

Topics

Related Companies

UsernamePublicRestriction

Register

MT142338

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel